Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1
Posted Sep 27 2012 8:00pm
Description of Invention: The invention describes the first identified anti-HIV human domain antibody (m36), which can potentially be used alone or synergistically with other anti-HIV antibodies and antiretroviral drugs as a therapeutic and/or preventative for HIV infection. It targets an epitope whose exposure is enhanced by binding of the HIV receptor CD4 to the HIV envelope glycoprotein (Env). M36 was identified by sequential panning of a newly developed large human VH library against Envs from different HIV-1 isolates. The antibody can neutralize HIV-1 primary isolates from different clades at low (nM) concentrations and due to its small size (14 kDa) is potentially able to efficiently penetrate lymphoid tissues where the virus replicates. The antibody is fairly well characterized and the inventors are generating derivatives of this antibody to improve the half-life and increase its potency and cross-reactivity.
Applications: Treatment and prevention of HIV infections
Advantages:
Human monoclonal antibody, thus eliminating some of the issues associated with humanized or murine monoclonal antibodies
Potential neutralization of HIV-1 primary isolates from different clades at nM concentrations
Relatively small size allows for potential efficient penetration into lymphoid tissues
NCI Press Release dated October 20, 2008 — Researchers Identify Novel Type of Antibody that Potently Inhibits HIV Infection [ Press Release ]
Collaborative Research Opportunity: The National Cancer Institute CCR Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize domain antibodies and nanoantibodies against HIV. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Licensing Information Please Contact: Sally Hu Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: hus@mail.nih.gov Phone: 301-435-5606 Fax: 301-402-0220
Description of Invention:
The invention describes the first identified anti-HIV human domain antibody (m36), which can potentially be used alone or synergistically with other anti-HIV antibodies and antiretroviral drugs as a therapeutic and/or preventative for HIV infection. It targets an epitope whose exposure is enhanced by binding of the HIV receptor CD4 to the HIV envelope glycoprotein (Env). M36 was identified by sequential panning of a newly developed large human VH library against Envs from different HIV-1 isolates. The antibody can neutralize HIV-1 primary isolates from different clades at low (nM) concentrations and due to its small size (14 kDa) is potentially able to efficiently penetrate lymphoid tissues where the virus replicates. The antibody is fairly well characterized and the inventors are generating derivatives of this antibody to improve the half-life and increase its potency and cross-reactivity.
Applications:
Treatment and prevention of HIV infections
Advantages:
Development Status:
In vitro data is available
Inventors:
Dimiter S Dimitrov (NCI)
Weizao Chen (NCI)
Patent Status:
HHS, Reference No. E-043-2008/0
PCT, Application No. PCT/US2009/030351 filed 07 Jan 2009
US, Application No. 12/811,998 filed 07 Jul 2010
Relevant Publication:
Collaborative Research Opportunity:
The National Cancer Institute CCR Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize domain antibodies and nanoantibodies against HIV. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Licensing Information Please Contact:
Sally Hu Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21,
Rockville, MD 20852
United States
Email: hus@mail.nih.gov
Phone: 301-435-5606
Fax: 301-402-0220
Ref No: 1809
Updated: 09/2012